Previous 10 | Next 10 |
WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the appoi...
The following slide deck was published by TScan Therapeutics, Inc. in conjunction with this event. For further details see: TScan Therapeutics (TCRX) Investor Presentation - Slideshow
TScan Therapeutics press release (NASDAQ:TCRX): FY GAAP EPS of -$4.17 beats by $5.49. Revenue of $10.1M (+818.2% Y/Y) misses by $1.22M. For further details see: TScan Therapeutics GAAP EPS of -$4.17 beats by $5.49, revenue of $10.1M misses by $1.22M
Received FDA clearance of IND for TSC-100 for the treatment of hematologic malignancies Phase 1 umbrella trial for liquid tumor program to initiate in H1 2022; preliminary data expected in H2 2022 Two INDs for TSC-200 series anticipated by year end Strong balance...
WALTHAM, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will pre...
– Phase 1 trial of TSC-100 expected to initiate in the first half of 2022 – – IND for TSC-101 on hold pending additional assessment of the risk of off-tumor reactivity – WALTHAM, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, ...
IND Submissions Completed in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Candidates TSC-100 and TSC-101 Lead TCR Identified for Solid Tumor Program Targeting HPV16; Further TCRs Advancing into IND-Enabling Activities with IND Submissions Planned for Second Half of 2022 ...
- Posters highlight discovery of TSC-101, manufacturing process and clinical development plan for liquid tumor candidates TSC-101 and TSC-102 - - Phase 1 clinical trial expected to initiate in the first half of 2021 - - Company to host virtual KOL event ...
WALTHAM, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that the Company will hos...
WALTHAM, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has completed the...
News, Short Squeeze, Breakout and More Instantly...
TScan Therapeutics Inc. Company Name:
TCRX Stock Symbol:
NYSE Market:
TScan Therapeutics Inc. Website:
2024-07-26 15:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-16 12:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-26 16:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...